Spots Global Cancer Trial Database for A Safety Study of SGN-CD19A for B-Cell Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Safety Study of SGN-CD19A for B-Cell Lymphoma
Official Title: A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With Relapsed or Refractory B-Lineage Non-Hodgkin Lymphoma
Study ID: NCT01786135
Interventions
Study Description
Brief Summary: This is a phase 1, open-label, dose-escalation, multicenter study to evaluate the safety and tolerability of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (B-NHL)
Detailed Description:
Eligibility
Minimum Age: 12 Years
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Alabama at Birmingham, Birmingham, Alabama, United States
City of Hope National Medical Center, Duarte, California, United States
Stanford Cancer Center, Stanford, California, United States
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
MD Anderson Cancer Center / University of Texas, Houston, Texas, United States
Contact Details
Name: Ana Kostic, MD
Affiliation: Seagen Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
